Arca Biopharma | ABIO - Cash And Equivalent


Arca Biopharma reported $49.52M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Amgen USD 12.04B 2.91B Mar/2026
Arca Biopharma USD 49.52M 2.58M Mar/2026
Biogen USD 3.38B 374.2M Mar/2026
Brainstorm Cell Therapeutics USD 15K 14K Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Capricor Therapeutics USD 105.42M 182.42M Mar/2026
Cipla INR 7.96B 39.9M Sep/2025
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 90.6M 83.14M Dec/2025
CSL USD 2.16B 633M Jun/2025
Cytokinetics USD 129.84M 7.32M Mar/2026
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
Gilead Sciences USD 7.56B 234M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Grifols EUR 979.78M 334.84M Dec/2024
Laboratory Of America USD 981.1M 448.8M Mar/2026
Myriad Genetics USD 124.4M 25.2M Mar/2026
Otsuka Holdings JPY 534.64B 123.53B Dec/2025
Pfizer USD 1.7B 561M Mar/2026
United Therapeutics USD 1.28B 277.4M Mar/2026